Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi ® (tafasitamab) in combination with rituximab and lenalidomide for adult ...
Lunsumio VELO reduces administration time from 2-4 hours to approximately one minute –– Availability of Lunsumio VELO allows ...
Availability of Lunsumio VELO allows treatment aligned to people’s clinical needs and personal preferences Approval supported by data demonstrating compelling complete response rate in third-line or ...
Basel: Roche has received approval from the US Food and Drug Administration (FDA) for CD20xCD3 bispecific Lunsumio VELO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback